Aprea Therapeutics Q1 net loss $4.4M; cash runway into Q3 2024; ATRN-119 Phase 1 data expected Q1 2024

Aprea Therapeutics, Inc.

2023-Q1 EPS reported -$1.34

Net loss of $4.4M ($1.34 per share) on $31.0M cash; operating loss $4.6M vs $8.1M YoY.
R&D expenses $1.3M (down from $4.1M YoY) due to legacy trial closeout; G&A $3.4M.
ATRN-119 Phase 1/2a enrollment continues; initial safety, tolerability, PK data expected Q1 2024.
ATRN-1051 IND-enabling studies ongoing; IND filing anticipated by end of 2023.
Closed $4.9M net proceeds from February public offering; appointed Dr. Gabriela Gruia to board.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aprea Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $4.4 million, EPS $1.34 per basic share.

Period: the quarter ended March 31, 2023
Net income: net loss of $4.4 million
EPS: $1.34 per basic share
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.4 million ($1.34 per basic share) on approximately 3.3 million weighted-average common shares outstanding for the quarter ended March 31, 2023

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-009864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.